Biometrics

U.S. Clinical Laboratory Tests Market Outlook & Forecast 2024-2029 Featuring Prominent Vendors - Eurofins Scientific, Laboratory Corp of America, Mayo Clinic, OPKO, Quest Diagnostics, Siemens, Sonic - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, Telemedicine, Virtual Medicine, Biometrics, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, Cloud, Hospital, Diagnosis, Machine learning, COVID, Hematology, Disease, COVID-19, Patient, Pharmacy, Public, AI, Laboratory, Insurance, Labcorp, City, Robotics, Cloud computing, Microbiology, Antibody, Toxicology, Medicare, Collection, USD, Data management, Government, Endocrinology, Physician, Immunochemistry, Quest Diagnostics

Based on that, the competitive landscape in the country for the clinical laboratory test market is highly localized and challenging.

Key Points: 
  • Based on that, the competitive landscape in the country for the clinical laboratory test market is highly localized and challenging.
  • The U.S. clinical laboratory tests market by providers is segmented into hospital-based clinical laboratories, independent laboratories, physician office laboratories, and others.
  • The U.S. clinical laboratory tests market by test type is segmented into clinical & immunochemistry, molecular diagnostics, hematology, microbiology & cytology, and toxicology.
  • Clinical and immunochemistry types of clinical lab tests account for a higher market share and dominate other tests.

Lyric Health Selects Reperio Health as Exclusive Partner for At-home Biometric Health Screenings

Retrieved on: 
Tuesday, March 26, 2024
Managed Care, Software, Mobile, Wireless, Telemedicine, Virtual Medicine, Biometrics, Apps, Applications, Technology, Medical Devices, Fitness & Nutrition, Biotechnology, Practice Management, Health, Diabetes, Risk, Tex, Stroke, FDA, Hypertension, Telehealth, Mobile phone

Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today a new client relationship with Lyric Health , an award-winning virtual primary care company based in McKinney, Tex.

Key Points: 
  • Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today a new client relationship with Lyric Health , an award-winning virtual primary care company based in McKinney, Tex.
  • Lyric Health will now offer its nationwide network access to Reperio’s at-home biometric health screening kits with instant results.
  • More than six million Lyric members will have access to Reperio’s patient-centric health screenings, empowering them with data and insights that can prevent health issues before they escalate into expensive and chronic conditions.
  • Added Naomi Levinthal, Chief Growth Officer of Reperio, “Lyric Health provides everything a member needs to navigate their health journey.

Tivic Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Medical Devices, Biometrics, Health, Health Technology, Research, Congestion, VNS, GHP, Telephone, Vagus nerve stimulation, Medical device, Security (finance), Bank statement, System, Marketing, FDA, Advertising, Cryptocurrency

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023.
  • “2023 was a year for both streamlining our commercial business and defining new opportunities for value creation,” stated Jennifer Ernst, CEO of Tivic.
  • Research and development expenses were approximately $1.7M for each of the years ended December 31, 2023 and December 31, 2022.
  • Management will host a webcast/conference call on Monday, March 25, 2024, at 1:30 PM PT / 4:30 PM ET to discuss the company’s year-end 2023 financial results and provide a business update, including comments on research directions undertaken in 2023.

Toyoda Gosei Invests in Yuurea, Inc., a Startup Developing Urine Test Kits for Easy Checks of Physical Condition

Retrieved on: 
Monday, March 25, 2024
Men, Health, Finance, Biometrics, Consumer, Small Business, Professional Services, Telemedicine, Virtual Medicine, Medical Devices, Start-Up, General Health, Health Technology, Women, Seniors, Multimedia, Molina Healthcare, Longevity, Investment, Gosei

View the full release here: https://www.businesswire.com/news/home/20240324521742/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240324521742/en/
    Test kit developed by Yuurea, Inc. (Photo: Business Wire)
    Yuurea aims to spread services that will lead to improved health habits by combining urine test kits with a smartphone app.
  • Yuurea’s app is used to photograph urine test strips and instantly analyze nutritional status and more with the company’s original image processing technology.
  • Toyoda Gosei is committed to collaborating with other companies and developing products in the field of preventive medicine as a way to help society deal with the challenges brought on by increased longevity.
  • * Investment made in March 2024, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.

CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose combination tablet as treatments for hypercholesterolaemia and significantly reducing cardiovascular events

Retrieved on: 
Friday, March 22, 2024
Health, Biometrics, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Hypercholesterolemia, European Commission, Bempedoic acid, Risk, Patient, Tablet, Committee, ACL, Ageing, Agent handling, Esperion Therapeutics, EMA, Death, European Medicines Agency, Ezetimibe, Therapy, Moyamoya disease, ATP, FDC, CHMP, Apolipoprotein, Pharmaceutical industry

“The positive CHMP opinion is a crucial milestone towards improved treatment outcomes, as we are now able to address even better the unmet needs of cardiovascular care and prevention among patients in Europe.

Key Points: 
  • “The positive CHMP opinion is a crucial milestone towards improved treatment outcomes, as we are now able to address even better the unmet needs of cardiovascular care and prevention among patients in Europe.
  • This first-in-class medicine with proven efficacy in reducing hypercholesterolaemia and preventing cardiovascular risks, is a testament to our tireless efforts to help improve the cardiovascular treatment landscape.
  • The CHMP is a scientific committee of the EMA that reviews medical product applications on their scientific and clinical merit.
  • The European Commission will review the CHMP opinions and is expected to deliver its final decision in the mid of the year 2024.

Global Digital Biomarkers Market Outlook & Forecast 2024-2029: Rise in Digitized Virtual Clinical Research, Increasing Focus on Drug Development and Expanding Applications in Mental Health - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
Mobile, Wireless, Other Technology, Telecommunications, Other Science, Data Analytics, Pharmaceutical, Research, Hardware, Mental Health, Medical Devices, Data Management, Consumer Electronics, Wearables, Mobile Technology, Technology, Women, Science, Biotechnology, Seniors, Biometrics, Medical Supplies, Men, Health, Artificial Intelligence, Health Technology, Professional Services, Health Insurance, Consumer, Cardiology, Culture, Conditional sentence, Growth, Prevalence, Neurology, Digital, Vital signs, COVID-19, Patient, Heart rate, Tablet, Biomarker, Health care, Software, Diagnosis, Drug development, USD, Ageing, Medical imaging

Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers.

Key Points: 
  • Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers.
  • The rise in digitized virtual clinical research is a significant trend in the global digital biomarkers market, driven by advances in remote monitoring technologies and the need for more efficient, patient-centric clinical trials.
  • The global digital biomarkers market is witnessing a notable trend with an increasing focus on drug development.
  • A prominent trend in the global digital biomarkers market is the increasing number of vendor collaborations and partnerships.

World Obesity Drugs and Delivery Platforms Research Report 2023: Pipeline Analysis, Drug Delivery Innovations, Outlook, Acquisitions, Partnerships, and Funding - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
General Health, Biometrics, Health, Fitness & Nutrition, Pharmaceutical, Obesity, Probiotic, Risk, Mineral, Prognosis, Bariatric surgery, Weight loss, BMI, Vitamin, Body mass index, Clinical trial, Mortality, Nutrient, Developed country, Overalls, Fast food

The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering.
  • In this study, the emerging and recently approved obesity treatment pipelines and associated advances in drug delivery technologies are analyzed.
  • The study also provides insights into funding, the collaborative landscape of obesity treatments and delivery platforms, the clinical trial landscape for obesity management, and the mechanism of action of promising anti-obesity drug candidates.
  • GLP-1-based obesity treatments are fast emerging as potent treatment options for obesity and have a favorable safety profile.

BostonGene Announces Participation at the United States and Canadian Academy of Pathology 113th Annual Meeting

Retrieved on: 
Thursday, March 21, 2024
Software, Research, Professional Services, Pharmaceutical, Oncology, Biometrics, Technology, Artificial Intelligence, Health Technology, Data Analytics, Science, Biotechnology, Health, MD, Baltimore Convention Center, USCAP, Marie Cassidy, Doctor of Philosophy

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 113th Annual Meeting, the largest gathering of pathologists in the world.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 113th Annual Meeting, the largest gathering of pathologists in the world.
  • The event will be held from March 23 - 28, 2024, at the Baltimore Convention Center in Baltimore, Maryland.
  • Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, along with members of the BostonGene team, will showcase the power of next-generation multi-platform AI-driven analytics.
  • This innovative approach aims to uncover crucial correlations between tumor genomics, patient immune profiles and treatment efficacy, driving advancements in personalized medicine.

Babson Diagnostics to Launch Transformative Blood Testing Service with Leading Retail Partners

Retrieved on: 
Thursday, March 21, 2024
Supermarket, Health Technology, Pharmaceutical, Oncology, Teens, Medical Devices, Parenting, Infectious Diseases, Retail, Genetics, Fitness & Nutrition, Cardiology, Health, Seniors, Practice Management, Men, General Health, Family, Consumer, Diabetes, Other Retail, Other Health, Biometrics, Diagnosis, Temperature, Patient, Pharmacy, Pharmacist, Prescription, Babson, Insurance, Centrifugation, Texas Pharmacy Association, Collection, Blood, FDA

Babson Diagnostics, a science-first health technology company, announced today that it will launch BetterWay™ blood testing with three retail partners in Austin and San Antonio.

Key Points: 
  • Babson Diagnostics, a science-first health technology company, announced today that it will launch BetterWay™ blood testing with three retail partners in Austin and San Antonio.
  • BetterWay brings blood testing into the 21st century, making it less invasive, more convenient, and accessible for consumers.
  • “Blood testing hasn’t changed much in over 70 years,” said David Stein, Babson’s chief executive officer.
  • Without the need for a phlebotomist, Babson can bring medically accurate blood testing to new, more convenient settings such as community pharmacies.

Koneksa Announces Merck Joins Data Syndication Partnership Program Around Parkinson’s Digital Biomarkers Observational Study

Retrieved on: 
Wednesday, March 20, 2024
Mobile, Wireless, Hardware, Data Management, Biometrics, Consumer Electronics, Technology, Health Technology, Clinical Trials, Nanotechnology, Neurology, Biotechnology, Wearables, Mobile Technology, Health, MSD, Observational study, IPhone, Biomarker, Merck & Co., Drug development, Translational medicine

Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, known as MSD outside of the United States and Canada, has joined its Data Syndication Partnership program for the LEARNS observational study, which seeks to develop digital biomarkers in neurodegenerative disorders from smart phone-based assessments and wearable technologies.

Key Points: 
  • Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, known as MSD outside of the United States and Canada, has joined its Data Syndication Partnership program for the LEARNS observational study, which seeks to develop digital biomarkers in neurodegenerative disorders from smart phone-based assessments and wearable technologies.
  • As a member, Merck researchers will have real-time access to data and results from the ongoing study.
  • The high-precision longitudinal data and in-clinic data from the LEARNS study will guide future development of digital biomarkers of disease progression in Parkinson’s disease.
  • Data syndication gives partners immediate and continuous access to data and results as the study progresses, and access to the study dashboard from Koneksa’s proprietary platform for real-time study monitoring, enabling syndication partners to learn from the study as it progresses.